← Leaderboards
Chiung-Kuei Huang
Indiana University Indianapolis
$2,106,414
Attributed
$2,106,414
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $862.5K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,106,414 · 4
By mechanism
R01$1,288,524 · 2
R21$817,890 · 2
Top collaborators
No co-investigators on record.
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Naga P. Chalasani$27,144,645
- Randal J. Kaufman$37,816,764
- Suthat Liangpunsakul$8,638,123
- Evan L Fogel$7,933,802
- Mark Sebastian Sulkowski$12,713,668
Others in their field
Other Emerging Leaders on “Hepatic”
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Thomas Denny · Duke University$23,095,705
- Virginia Kan · George Washington University$13,363,264
- Sujatha Rashid · American Type Culture Collection$10,735,388
- Mark Marino · Venturewell$10,702,845
- Samer Gawrieh · Indiana University Indianapolis$9,356,353
Research focus
HepaticMediatingHepatocyteLiver FibrosisAlcoholsAffectKnock-OutLiverLinkDisease ProgressionCirrhosisCause Of DeathDna MethylationDisease ModelAlcoholic Liver DiseasesDioxygenasesKnock-DownEnzymesDown-RegulationChronicEpigenetic ProcessEthanolFeedingIn Vivo
Grant awards (7)
TET1 and sex differences in alcohol associated liver tumorigenesis$477,626
R01 · FY2025 · AA · contact PI
TET1 in non-alcoholic fatty liver disease development$384,829
R01 · FY2025 · DK · contact PI
TET1 in non-alcoholic fatty liver disease development$426,069
R01 · FY2024 · DK · contact PI
Aspartate beta-hydroxylase and DNA damage in chronic liver diseases$181,688
R21 · FY2024 · AA · contact PI
Aspartate beta-hydroxylase and DNA damage in chronic liver diseases$219,579
R21 · FY2023 · AA · contact PI
TET1 in alcoholic liver disease progression$175,727
R21 · FY2021 · AA · contact PI
TET1 in alcoholic liver disease progression$240,896
R21 · FY2020 · AA · contact PI